Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CV Sciences (CVSI) EBITDA (2016 - 2025)

CV Sciences (CVSI) has disclosed EBITDA for 14 consecutive years, with -$75000.0 as the latest value for Q4 2025.

  • Quarterly EBITDA rose 88.39% to -$75000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$470000.0 through Dec 2025, up 78.54% year-over-year, with the annual reading at -$470000.0 for FY2025, 78.54% up from the prior year.
  • EBITDA hit -$75000.0 in Q4 2025 for CV Sciences, up from -$275000.0 in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $5.8 million in Q1 2023 to a low of -$8.8 million in Q4 2021.
  • Historically, EBITDA has averaged -$1.1 million across 5 years, with a median of -$633000.0 in 2024.
  • Biggest YoY gain for EBITDA was 480.33% in 2023; the steepest drop was 220.46% in 2023.
  • Year by year, EBITDA stood at -$8.8 million in 2021, then surged by 133.78% to $3.0 million in 2022, then tumbled by 220.46% to -$3.6 million in 2023, then soared by 82.05% to -$646000.0 in 2024, then surged by 88.39% to -$75000.0 in 2025.
  • Business Quant data shows EBITDA for CVSI at -$75000.0 in Q4 2025, -$275000.0 in Q3 2025, and -$131000.0 in Q2 2025.